Heghine Khachatryan: Novel Biomarkers for Cancer-Associated Thrombosis
Heghine Khachatryan, Editor-in-Chief of Hemostasis Today, Head of Hemophilia and Thrombosis Center at Yeolyan Hematology and Oncology Center, shared Journal of Thrombosis and Haemostasis (JTH)’s post on LinkedIn, adding:
“A highly promising contribution to the field of cancer-associated thrombosis.
The identification of novel plasma proteomic biomarkers has the potential to transform risk stratification by enabling earlier, more accurate, and personalized prediction of thrombotic events in patients with malignancy.
Integrating biomarker discovery with advanced proteomics and machine learning may pave the way toward precision medicine, optimized thromboprophylaxis, and improved clinical outcomes.
Further validation in large, multicenter prospective cohorts will be essential before routine clinical implementation.
Congratulations to the authors on this outstanding and clinically relevant work.”
Journal of Thrombosis and Haemostasis (JTH) shared a post on LinkedIn about a recent article by Preeti et al., adding:
“Development of novel plasma proteomic biomarkers for cancer-associated thrombosis in an advanced cancer cohort
Affinity-based plasma proteomics flagged early cancer-associated thrombosis.
In a nested case-control study of 57 cases and 113 matched controls across five cancer types, a random survival forest model screening 5,416 proteins predicted 30-day thrombosis well (ROC 0.83), though accuracy fell by 180 days.
Top proteins sat in platelet activation, fibrin formation, and complement pathways.”
Title: Development of novel plasma proteomic biomarkers for cancer-associated thrombosis in an advanced cancer cohort
Authors: Preeti, Mrinal Ranjan, Dang Pham, Juan L Bueno, Micheline M Resende, Michael E Scheurer, Christopher I Amos, Chao Cheng, Ang Li

Other posts featuring Heghine Khachatryan and Journal of Thrombosis and Haemostasis on Hemostasis Today.
-
Nov 18, 2026, 01:45Shikha Jha: My Takeaways from the 4th GANSID International Congress
-
Nov 18, 2026, 01:34Zeeshan Ahmed Khattak: Treatment of Fever and Neutropenia in Hematology/Oncology and Hematopoietic Cell Transplant Patients
-
Nov 17, 2026, 23:45Cajetan Reichardt: LAAO vs. OAC in AF – Balancing Nonprocedural Bleeding and Ischemic Stroke Risk
-
Nov 17, 2026, 23:42Brian Tegtmeyer: Expanding Pre-Hospital Administration of Low-Titer O Positive Whole Blood
-
Nov 17, 2026, 23:41Mansi Kala: Advancing Hematology – From Evidence to Clinical Excellence
-
Nov 17, 2026, 23:40Nathan Connell: Registered for the WFH Comprehensive Care Summit 2027 in Prague
-
Nov 17, 2026, 23:38Yaariv Khaykin: Does Reducing AF Burden After Ablation Change the Need for Anticoagulation?
-
Nov 17, 2026, 23:38Amos Gitonga Mbaabu: Strengthening Care and Advocacy for Haemophilia and SCD across Southern Africa
-
Nov 17, 2026, 23:35Muhammad Sameed Altaf: A Decade of Working Together for Thalassemia Awareness and Patient Support